Savara Inc. (SVRA)
- Previous Close
4.6400 - Open
4.6200 - Bid 4.4600 x 200
- Ask 4.5200 x 100
- Day's Range
4.4400 - 4.6400 - 52 Week Range
3.1150 - 5.7000 - Volume
4,680,635 - Avg. Volume
1,805,211 - Market Cap (intraday)
739.058M - Beta (5Y Monthly) 0.96
- PE Ratio (TTM)
-- - EPS (TTM)
-0.4200 - Earnings Date Nov 7, 2024 - Nov 11, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
10.79
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. is headquartered in Langhorne, Pennsylvania.
www.savarapharma.comRecent News: SVRA
View MorePerformance Overview: SVRA
Trailing total returns as of 9/20/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SVRA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SVRA
View MoreValuation Measures
Market Cap
740.70M
Enterprise Value
645.82M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
7.28
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-38.80%
Return on Equity (ttm)
-79.48%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-75.29M
Diluted EPS (ttm)
-0.4200
Balance Sheet and Cash Flow
Total Cash (mrq)
121.92M
Total Debt/Equity (mrq)
26.35%
Levered Free Cash Flow (ttm)
-40.99M